...raised in the round to €29 million ($32.9 million). Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund...
...a modulable multiple-antigen cargo. Amal Therapeutics S.A., Geneva, Switzerland Jaime De Leon Amal Therapeutics S.A. BioMedPartners Boehringer Ingelheim Venture Fund Helsinn Investment Fund High-Tech...

...raised in the round to €29 million ($32.9 million). Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund...
...TLR) peptide agonist adjuvant and a modulable multiple-antigen cargo. Jaime De Leon Amal Therapeutics S.A. BioMedPartners Boehringer Ingelheim Venture Fund Helsinn Investment Fund High-Tech...

...see "Signal Mapping" ). The companies said existing NovellusDx shareholders including OrbiMed Israel Partners, Pontifax, Helsinn Investment Fund...

...as did existing investors Alexandria Venture Investments, Arch Venture Partners, HT Family Office, Canaan Partners, Helsinn Investment Fund...

...as did existing investors Alexandria Venture Investments, Arch Venture Partners, HT Family Office, Canaan Partners, Helsinn Investment Fund...

...Bristol-Myers Squibb Co. (NYSE:BMY) and New Enterprise Associates (NEA). Inova Strategic Investments, Co-win Healthcare Fund, Helsinn Investment Fund...

...Bristol-Myers Squibb Co. (NYSE:BMY) and New Enterprise Associates (NEA). Inova Strategic Investments, Co-win Healthcare Fund, Helsinn Investment Fund...

...first close of a series B round co-led by Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund...

...a series A round led by Hermed Capital. Celgene Corp. (NASDAQ:CELG), Vivo Capital, Decheng Capital, Helsinn Investment Fund...

...A led by Hermed Capital. Also participating were Celgene Corp. (NASDAQ:CELG), Vivo Capital, Decheng Capital, Helsinn Investment Fund...